Analysis of Prothrombin Time in Hepatitis C Patients
DOI:
https://doi.org/10.71395/ijhp.2.1.2025.45-49Abstract
Background and Objectives: Various clotting proteins are synthesized in the liver and any impairment in the liver results in multiple coagulation abnormalities. To determine the prevalence of increased level of Prothrombin Time (PT) in patients with cirrhosis and to compare the levels of Prothrombin Time along with International Nor malized Ratio (INR) in patients of Hepatitis C with and without Liver Cirrhosis.
METHODOLOGY: A retrospective study was conducted in Sheikh Zaid Hospital, Lahore in the Gastroenterolo gy department. The study was conducted during the 3 months from May to July, 2023. The study involved 80 patients, out of which 43 were females and 37 were males with multiple age groups ranging from 30 to 85 years. These patients were further divided into 55 patients with Hepatitis C without liver cirrhosis and 25 patients with Hepatitis C with liver Cirrhosis. Immuno-Assay Special Chemistry Analyzer (Access 2) and Sysmex CS-1600 were used to detect the HCV positive patients and to analyze the coagulation profile. A self-designed Performa was used to collect the patient data. Data were entered and analyzed by using excel and displayed by using Tables and Bar Charts.
RESULTS: The results indicated that out of 80 patients Prothrombin Time (PT) was normal in 26 patients of Hep atitis C without Cirrhosis, high in 34 patients of Hepatitis C with and without Cirrhosis, and extremely high in 10 patients of Hepatitis C with Cirrhosis. Similarly, International Normalized Ratio (INR) was normal in 14 patients of Hepatitis C without Cirrhosis, high in 59 patients of Hepatitis C with and without Cirrhosis, and abnormally high in 7 patients of Hepatitis C with Cirrhosis.
CONCLUSION: The conclusion of this study is the abnormalities in the coagulation parameter like Prothrombin Time (PT) depend on the severity and intensity of liver disease.
References
Khan MA. Comparative prevalence of different types of viral hepatitis in the district Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan. Egyptian Liver Journal. 2022;12(1):40.
Haqqi A, Munir R, Khalid M, Khurram M, Zaid M, Ali M, et al. Prevalence of hepatitis C virus geno types in Pakistan: current scenario and review of literature. Viral immunology. 2019;32(9):402-13.
Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359-76.
Mustafa ME, Mansoor MM, Mohammed A, Babker A. Evaluation of platelets count and coagulation parameters among patients with liver disease. World Journal of Pharmaceutical Research. 2015;4(10):360-8.
Páramo JA, Rocha E, editors. Hemostasis in advanced liver disease. Seminars in thrombosis and hemostasis; 1993: Copyright© 1993 by Thieme Medical Publishers, Inc. Scheig R. Evaluation of tests used to screen patients with liver disorders. Primary Care: Clinics in Office Practice. 1996;23(3):551-60.
Li J, Han B, Li H, Deng H, Méndez-Sánchez N, Guo X, et al. Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis. Saudi Journal of Gastroenterology: Offi cial Journal of the Saudi Gastroenterology Associa tion. 2018;24(4):220.
AL-Dewachi SO, Kashmoola MA. Evaluation of coagulation parameters in patients with chronic liver diseases. Med J Tikrit. 2013;19(2):305-14.
Kujovich JL. Hemostatic defects in end stage liver disease. Critical care clinics. 2005;21(3):563-87.
Rapaport S. Coagulation problems in liver disease. Blood coagulation 2000;11:S69-S74. & fibrinolysis. Garg RP, Agrawal A, Bhake AS, Vagha S. Correla tion study of coagulation profile in spectrum of liver diseases. Journal of Evolution of Medical and Dental Sciences-JEMDS. 2020;9(8):549-54.
Morozov VA, Lagaye S. Hepatitis C virus: Morpho genesis, infection and therapy. World journal of hepatology. 2018;10(2):186.
Simmonds P. The origin of hepatitis C virus. Hepa titis C virus: from molecular virology to antiviral therapy. 2013:1-15.
Schmelzer J, Dugan E, Blach S, Coleman S, Cai Z, DePaola M, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. The lancet Gastroenterology & hepatology. 2020;5(4):374-92.
Kotadiya TP, Khant V, Prajapati B. A study of coag ulation profile in diseases of liver: At tertiary care center hospital. Indian Journal of Pathology and Oncology. 2019;6(1):107-11.
Saner FH, Kirchner C. Monitoring and treatment of coagulation disorders in end-stage liver disease. Viszeralmedizin. 2016;32(4):241-8. Kandemir Ö, Polat G, Saraçoğlu G, Taşdelen B. The predictive role of AST level, prothrombin time, and platelet count in the detection of liver fibrosis in patients with chronic hepatitis C. Turkish Journal of Medical Sciences. 2009;39(6):857-62.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 International Journal of Healthcare Professions
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments ijhp@giu.edu.pk
